GILMAN STEVEN C
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
AKBA sees no direct news updates this week. In the past week, there were no company‑specific announcements for Akebia Therapeutics (AKBA). The only notable filing was SCYNEXIS appointing Dr. Steven K. Burke to its board, which does not involve AKBA. As a result, there is little new information to affect AKBA’s market perception at this time.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Truist lowers Vericel price target to $52. Truist Securities maintained its positive stance on Vericel but reduced its price target to $52. This adjustment places the new target below the current average analyst estimate of $60.57. The move reflects a cautious outlook despite the firm's continued positive assessment of the company.
Transaction History
| SCYX | ▲ Buy | Grant | 23,000 | $0 | 6/26/2025 | View on chart |
| AKBA | ▲ Buy | Grant | 35,700 | $0 | 6/10/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 5,833 | $76K | 10/16/2024 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,833 | $241K | 10/16/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 5,833 | $76K | 10/2/2024 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,833 | $235K | 10/2/2024 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,834 | $266K | 9/18/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 5,834 | $76K | 9/18/2024 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,000 | $243K | 9/4/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 5,000 | $19K | 9/4/2024 | View on chart |
| SCYX | ▲ Buy | Grant | 23,000 | $0 | 6/20/2024 | View on chart |
| AKBA | ▲ Buy | Grant | 30,000 | $0 | 6/6/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,200 | — | 5/1/2024 | View on chart |
| SCYX | ▲ Buy | Grant | 10,000 | $0 | 6/15/2023 | View on chart |
| AKBA | ▲ Buy | Grant | 30,000 | $0 | 6/6/2023 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 2,600 | — | 4/27/2023 | View on chart |
| SCYX | ▲ Buy | Grant | 10,000 | $0 | 6/17/2022 | View on chart |
| AKBA | ▲ Buy | Grant | 13,700 | $0 | 6/8/2022 | View on chart |
| AKBA | ▼ Sell | Open Market | 4,567 | $2K | 6/3/2022 | View on chart |
| VCEL | ▼ Sell | Open Market | 900 | $28K | 4/29/2022 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 2,600 | — | 4/27/2022 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 5,000 | $19K | 11/29/2021 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,000 | $196K | 11/29/2021 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 5,000 | $19K | 10/27/2021 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,000 | $253K | 10/27/2021 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 5,000 | $19K | 9/30/2021 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,000 | $244K | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
SCYNEXIS Wins $214M BARDA Contract for SCY-247
SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.
SCYNEXIS Wins $214M BARDA Contract for SCY-247. SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.